<DOC>
	<DOCNO>NCT01142154</DOCNO>
	<brief_summary>This study compare exposure orally administer Prodarsan intravenous dose Osmitrol ( 10 % solution ) Cockayne Syndrome ( CS ) patient . Also pharmacokinetics single multiple orally dose Prodarsan evaluate compare intravenous dose Osmitrol CS patient .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study Single Multiple Oral Doses Prodarsanâ„¢ Patients With Cockayne Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cockayne Syndrome</mesh_term>
	<criteria>Parents legal guardian ( ) pediatric patient CS must willing able give write Informed Consent . Informed Assent offer child understand participate Informed Assent process . Diagnosis CS confirm one follow laboratory diagnostic test result : Demonstration molecular diagnostic analysis two mutation either ERCC6 gene ERCC8 gene , wherein mutation either know pathogenic obviously detrimental ( include nonsense frameshift mutation , mutation `` invariant '' splice site consensus signal , large deletions/rearrangements ) ; OR A pattern DNA repair responses patient 's cultured skin fibroblast cell indicative specific deficiency transcriptioncoupled DNA nucleotide excision repair irradiation ultraviolet light , namely significant deficiency cellular survival ( and/or `` recovery ribonucleic acid [ RNA ] synthesis , '' specifically measure ) couple normal test `` unscheduled DNA synthesis '' OR Decreased cell survival and/or `` recovery RNA synthesis '' UVirradiated patient 's skin fibroblast culture rescue parameter fusion reference cell line know NER defect ( functional complementation analysis ) OR Quantitative RTPCR quantify mRNA level CSA CSB transcript . Weight inclusive 10 kg 25 kg . Male female , inclusive two ( 2 ) ten ( 10 ) year age . Clinically acceptable hematocrit judge Principal Investigator ( PI ) . The investigator opinion patient caregiver willing able comply protocol requirement . Any concurrent illness ( related CS ) , disability clinically significant abnormality , include laboratory test , may affect interpretation PK safety data prevent patient safely complete assessment require protocol judged investigator . Such condition include , limited : Ascites generalize edema . Nephrotic syndrome history abnormal kidney function . Clinically significant thyrotoxicosis . Known history hyperprolinemia . Clinically significant dehydration judge investigator Severely compromise venous access . Presence external ventricular , abdominal , chest drain . Subjects due receive radioiodine therapy , two ( 2 ) week two ( 2 ) week follow study period . Participation another PK treatment clinical study within thirty ( 30 ) day prior sign date Informed Consent/Assent Form study . As judged investigator , clinical feature present time initial screening , associate terminal phase natural progression CS , indicate safe travel completion study assessment unlikely , include follow : Continuous intermittent dependence supplemental oxygen home six ( 6 ) month prior enrollment study ; OR Two hospitalization due pneumonia , twelve ( 12 ) month prior enrollment study ; OR A documented , net weight loss least 10 % , recover , include significant net weight loss ( beyond estimate error measurement ) recent 6 month despite intensive nutritional support include use gastrostomy tube feeding . Known hypersensitivity component find Prodarsan , Dmannitol , iohexol iodine compound . History clinically significant drug sensitivity allergic reaction anaphylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Cockayne Syndrome</keyword>
	<keyword>Ageing</keyword>
	<keyword>pediatrics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Prodarsan</keyword>
	<keyword>Dwarfism</keyword>
	<keyword>Genetic disease , inborn</keyword>
	<keyword>DNA Repair-Deficiency Disorders</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Safety</keyword>
</DOC>